Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

INTRODUCTION: Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib. In this post hoc analysis, we describe the acne events in Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Nobukazu, Ikeda, Masanori, Liu, John, Raymundo, Eliza, Liu, Yingyi, Sasaki, Takuya, Yamasaki, Kenshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366050/
https://www.ncbi.nlm.nih.gov/pubmed/37356075
http://dx.doi.org/10.1007/s13555-023-00961-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366050/
https://www.ncbi.nlm.nih.gov/pubmed/37356075
http://dx.doi.org/10.1007/s13555-023-00961-9

Ejemplares similares